Serum concentrations of valproic acid in people with epilepsy: Clinical implication
Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions. Aims: To determine valproic acid concentrations in serum samples from people with epilepsy and to analyze...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
GarVal Editorial Ltda.
2022-11-01
|
| Series: | Journal of Pharmacy & Pharmacognosy Research |
| Subjects: | |
| Online Access: | https://jppres.com/jppres/pdf/vol10/jppres22.1500_10.6.1117.pdf |
| _version_ | 1811177798626181120 |
|---|---|
| author | Angel T. Alvarado Juan Cotuá Maryori Delgado Alexis Morales Ana María Muñoz César Li Amenero María R. Bendezú Jorge A. García Doris Laos-Anchante Felipe Surco-Laos Berta Loja Mario Bolarte-Arteaga Mario Pineda-Pérez |
| author_facet | Angel T. Alvarado Juan Cotuá Maryori Delgado Alexis Morales Ana María Muñoz César Li Amenero María R. Bendezú Jorge A. García Doris Laos-Anchante Felipe Surco-Laos Berta Loja Mario Bolarte-Arteaga Mario Pineda-Pérez |
| author_sort | Angel T. Alvarado |
| collection | DOAJ |
| description | Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions.
Aims: To determine valproic acid concentrations in serum samples from people with epilepsy and to analyze its clinical implications.
Methods: Cloned donor enzyme immunoassay; descriptive, cross-sectional, non-randomized, convenience recruitment study of 57 voluntary patients with epilepsy (n = 39 male, 68.42%; n = 18 female, 31.58%) aged between 19 and 62 years. After three months of treatment with valproic acid, a single blood sample was collected from each volunteer at a minimal concentration.
Results: Serum drug concentrations 51.30-100.10 mg/L (SD 5.94) and level/dose 2.17-5.31 (SD 1.14) were observed. Association was shown between the dose ratio/dose of valproic acid (R2 = 0.8693; p<0.05) and the Mann-Whitney U test (p<0.05). Valproic acid monotherapy and association with carbamazepine and phenytoin are not different between treatment groups (Mann-Whitney U test: p = 0.391 > α = 0.05).
Conclusions: Serum valproic acid concentrations are within the therapeutic range, and there is a significant inverse linear correlation between dose ratio/dose, which must be considered to personalize the dose and optimize the pharmacotherapeutic result. |
| first_indexed | 2024-04-11T06:08:22Z |
| format | Article |
| id | doaj.art-2fb84978ba024f9aaf67755e62c4e72b |
| institution | Directory Open Access Journal |
| issn | 0719-4250 |
| language | English |
| last_indexed | 2024-04-11T06:08:22Z |
| publishDate | 2022-11-01 |
| publisher | GarVal Editorial Ltda. |
| record_format | Article |
| series | Journal of Pharmacy & Pharmacognosy Research |
| spelling | doaj.art-2fb84978ba024f9aaf67755e62c4e72b2022-12-22T04:41:25ZengGarVal Editorial Ltda.Journal of Pharmacy & Pharmacognosy Research0719-42502022-11-0110611171125https://doi.org/10.56499/jppres22.1500_10.6.1117Serum concentrations of valproic acid in people with epilepsy: Clinical implicationAngel T. Alvarado0Juan Cotuá1Maryori Delgado2Alexis Morales3Ana María Muñoz4César Li Amenero5María R. Bendezú6Jorge A. García7Doris Laos-Anchante8Felipe Surco-Laos9Berta Loja10Mario Bolarte-Arteaga11Mario Pineda-Pérez12International Research Network of Pharmacology and Precision Medicine (REDIFMEP), Human Medicine, San Ignacio de Loyola University, La Molina 15024, Lima, Peru.Neurology and Neurosurgery of the Sabana Neurosabana, Sincelejo 700001, Colombia.Neurology and Neurosurgery of the Sabana Neurosabana, Sincelejo 700001, Colombia.Department of Toxicology and Pharmacology, Faculty of Pharmacy and Bioanalysis, Universidad Los Andes, 5101, Merida, Venezuela.Institute of Food Science and Nutrition, ICAN, San Ignacio de Loyola University, La Molina 15024, Lima, Peru.Outpatient Clinic, Victor Larco Herrera Hospital, 15076, Lima, Peru.Faculty of Pharmacy and Biochemistry, San Luis Gonzaga National University of Ica, 11004, Ica, Peru.Faculty of Pharmacy and Biochemistry, San Luis Gonzaga National University of Ica, 11004, Ica, Peru.Faculty of Pharmacy and Biochemistry, San Luis Gonzaga National University of Ica, 11004, Ica, Peru.Faculty of Pharmacy and Biochemistry, San Luis Gonzaga National University of Ica, 11004, Ica, Peru.Environmental Engineering, Faculty of Engineering, San Ignacio de Loyola University, La Molina 15024, Lima, Peru.Human Medicine, Continental University, Los Olivos 15304, Lima, Peru.Pharmacy and Biochemistry, Faculty of Health Sciences, Scientific University of the South, UCSUR, 15067, Lima, Peru.Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions. Aims: To determine valproic acid concentrations in serum samples from people with epilepsy and to analyze its clinical implications. Methods: Cloned donor enzyme immunoassay; descriptive, cross-sectional, non-randomized, convenience recruitment study of 57 voluntary patients with epilepsy (n = 39 male, 68.42%; n = 18 female, 31.58%) aged between 19 and 62 years. After three months of treatment with valproic acid, a single blood sample was collected from each volunteer at a minimal concentration. Results: Serum drug concentrations 51.30-100.10 mg/L (SD 5.94) and level/dose 2.17-5.31 (SD 1.14) were observed. Association was shown between the dose ratio/dose of valproic acid (R2 = 0.8693; p<0.05) and the Mann-Whitney U test (p<0.05). Valproic acid monotherapy and association with carbamazepine and phenytoin are not different between treatment groups (Mann-Whitney U test: p = 0.391 > α = 0.05). Conclusions: Serum valproic acid concentrations are within the therapeutic range, and there is a significant inverse linear correlation between dose ratio/dose, which must be considered to personalize the dose and optimize the pharmacotherapeutic result.https://jppres.com/jppres/pdf/vol10/jppres22.1500_10.6.1117.pdfdose-dose relationshipepilepsyserum concentrationtherapeutic monitoringvalproic acid |
| spellingShingle | Angel T. Alvarado Juan Cotuá Maryori Delgado Alexis Morales Ana María Muñoz César Li Amenero María R. Bendezú Jorge A. García Doris Laos-Anchante Felipe Surco-Laos Berta Loja Mario Bolarte-Arteaga Mario Pineda-Pérez Serum concentrations of valproic acid in people with epilepsy: Clinical implication Journal of Pharmacy & Pharmacognosy Research dose-dose relationship epilepsy serum concentration therapeutic monitoring valproic acid |
| title | Serum concentrations of valproic acid in people with epilepsy: Clinical implication |
| title_full | Serum concentrations of valproic acid in people with epilepsy: Clinical implication |
| title_fullStr | Serum concentrations of valproic acid in people with epilepsy: Clinical implication |
| title_full_unstemmed | Serum concentrations of valproic acid in people with epilepsy: Clinical implication |
| title_short | Serum concentrations of valproic acid in people with epilepsy: Clinical implication |
| title_sort | serum concentrations of valproic acid in people with epilepsy clinical implication |
| topic | dose-dose relationship epilepsy serum concentration therapeutic monitoring valproic acid |
| url | https://jppres.com/jppres/pdf/vol10/jppres22.1500_10.6.1117.pdf |
| work_keys_str_mv | AT angeltalvarado serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT juancotua serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT maryoridelgado serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT alexismorales serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT anamariamunoz serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT cesarliamenero serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT mariarbendezu serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT jorgeagarcia serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT dorislaosanchante serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT felipesurcolaos serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT bertaloja serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT mariobolartearteaga serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication AT mariopinedaperez serumconcentrationsofvalproicacidinpeoplewithepilepsyclinicalimplication |